1200 Pharma utilizes medicinal chemistry technologies to streamline pre-clinical drug discovery processes and reduce clinical trial timelines. By enhancing the efficiency of drug development, the company addresses the lengthy and costly nature of bringing new therapeutics to market.
Funding
$52.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The traditional drug discovery process is lengthy and expensive, often taking many years and requiring significant investment to bring new therapeutics to market. Inefficiencies in preclinical development and clinical trials contribute to these extended timelines and high costs.
Solution
1200 Pharma employs advanced medicinal chemistry technologies to accelerate preclinical drug discovery and shorten clinical trial durations. By optimizing the drug development pipeline, the company aims to reduce the time and expense associated with bringing novel therapeutics to patients. Their approach focuses on enhancing the efficiency of identifying and developing promising drug candidates.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to accelerate their drug discovery and development programs.
Features
- Medicinal chemistry technologies for streamlined drug discovery
- Focus on optimizing preclinical development processes
- Aims to reduce clinical trial timelines